Blood-brain barrier tight junction disruption by neuroinflammatory cytokines
Related Wiki Pages
Research Question
"Analyze how neuroinflammatory cascades disrupt blood-brain barrier (BBB) integrity through tight junction protein degradation. Key mechanisms to investigate: 1. TNF-alpha signaling cascade and its effects on claudin-5, occludin, and ZO-1 expression and localization 2. IL-1beta-mediated activation of MMPs (matrix metalloproteinases) that cleave tight junction proteins 3. IL-6 effects on BBB permeability and tight junction disruption 4. Therapeutic targets that could restore BBB integrity (e.g., MMP inhibitors, cytokine receptor blockers, tight junction protein stabilizers) Focus on: molecular mechanisms, therapeutic intervention points, and evidence for restoring BBB integrity in neurodegeneration."
Executive Summary
The synthesis reveals a clear winner in Palmitoylethanolamide (PEA) therapy, which scored highest (0.78) due to exceptional feasibility scores driven by its GRAS status, existing clinical trials (4 active neuroinflammation studies), and immediate Phase II potential with costs under $5M. The Clinical Trialist's identification of ongoing PEA trials (NCT04489017, NCT06777680) provides unprecedented validation opportunity. NET inhibition via PAD4 ranked second (0.70) with strong mechanistic plausibility and good druggability, though safety concerns regarding immune suppression tempered scores. The computational biology analysis confirmed tight junction protein interactions (OCLN-CLDN5 confidence 0.99, TJP1-CLDN5 confidence 0.993) supporting mechanistic connectivity across hypotheses.
The Wnt pathway approach fell to third (0.58) despite strong mechanistic scores due to the Clinical Trialist's critical revelation of tideglusib's Phase II Alzheimer's failure - a precedent that dramatically impacts regulatory feasibility and competitive landscape scores. Complex multi-target strategies ranked poorly due to implementation challenges, with the cross-tissue approach scoring lowest (0.36) due to speculative mechanistic connections and commercial impossibility. The synthesis identifies PEA as the immediate validation opportunity ($2-5M, 2-3 years) while PAD4 inhibition represents the optimal medium-term mechanistic bet requiring IND-enabling studies. The knowledge graph reveals robust connectivity between β-catenin and tight junction proteins, supporting the biological rationale even where clinical feasibility remains challenging.
Multi-Hypothesis Score Comparison
Comparing top 3 hypotheses across 8 scoring dimensions
Scientific Debate (6 rounds) View full transcript →
Multi-agent debate between AI personas, each bringing a distinct perspective to evaluate the research question.
Theorist
Generates novel, bold hypotheses by connecting ideas across disciplines
Based on the provided literature, I'll generate novel therapeutic hypotheses targeting BBB tight junction disruption in neurodegeneration:
Hypothesis 1: Wnt/β-catenin Pathway Restoration as BBB Stabilizer
Target: β-catenin/TCF4 signaling axis Description: Pharmacological activation of Wnt/β-catenin signaling could restore tight junction integrity by counteracting NF-κB-mediated suppres...Read full response (6,447 chars)
Based on the provided literature, I'll generate novel therapeutic hypotheses targeting BBB tight junction disruption in neurodegeneration:
Hypothesis 1: Wnt/β-catenin Pathway Restoration as BBB Stabilizer
Target: β-catenin/TCF4 signaling axis Description: Pharmacological activation of Wnt/β-catenin signaling could restore tight junction integrity by counteracting NF-κB-mediated suppression of endothelial barrier function. Small molecule Wnt agonists or GSK-3β inhibitors could stabilize β-catenin and enhance transcription of tight junction proteins. Supporting Evidence: PMID 40102948 demonstrates that Wnt3/β-catenin/TCF4 signaling restoration reduces BBB disruption in sepsis-associated encephalopathy. PMID 39427196 shows LPS suppresses brain endothelial Wnt/β-catenin signaling, and NF-κB p65 directly interacts with β-catenin to reduce barrier gene transcription (Figure 3 shows β-catenin/NF-κB co-localization). Predicted Outcomes: Enhanced claudin-5, occludin, and ZO-1 expression; reduced BBB permeability; improved cognitive outcomes Confidence: 0.8Hypothesis 2: Neutrophil Extracellular Trap (NET) Inhibition for BBB Protection
Target: PAD4 (Peptidylarginine Deiminase 4) or NET formation pathways Description: Systemic NET formation contributes to BBB disruption through inflammatory amplification. PAD4 inhibitors like GSK484 could prevent NET-mediated tight junction degradation by blocking the neutrophil-endothelial inflammatory cascade that compromises barrier integrity. Supporting Evidence: PMID 40102948 shows GSK484 (PAD4 inhibitor) significantly reduces BBB permeability and improves survival in sepsis models. Figure 4 demonstrates that NET inhibition reduces tight junction disruption and BBB permeability markers. Predicted Outcomes: Reduced neuroinflammation, preserved tight junction proteins, decreased brain water content Confidence: 0.75Hypothesis 3: Dual NF-κB/MMP Inhibition Strategy
Target: NF-κB p65 and matrix metalloproteinases Description: Combined inhibition of NF-κB activation and MMP activity could provide synergistic BBB protection by simultaneously blocking inflammatory transcription and preventing proteolytic degradation of tight junction proteins. This dual approach targets both upstream signaling and downstream effector mechanisms. Supporting Evidence: PMID 39427196 demonstrates that NF-κB inhibition restores Wnt/β-catenin signaling and reduces BBB leakage (Figure 4). The literature consistently shows MMP involvement in tight junction protein cleavage during neuroinflammation. Predicted Outcomes: Superior BBB integrity preservation compared to single-target approaches; reduced inflammatory gene expression; maintained tight junction protein levels Confidence: 0.7Hypothesis 4: Peripheral-to-Central Inflammation Circuit Breaker
Target: Systemic inflammatory mediators (IL-1β, TNF-α) at blood-brain interface Description: Targeted delivery of anti-inflammatory agents to brain endothelium could interrupt the peripheral-to-central inflammation transmission without systemic immunosuppression. Endothelial-targeted nanoparticles carrying cytokine receptor antagonists could selectively protect the BBB. Supporting Evidence: PMID 37245027 shows that peripheral Pseudomonas pneumonia induces neuroinflammation and BBB dysfunction without direct brain infection (Figure 2 shows BBB permeability and tight junction disruption). This demonstrates peripheral-to-central inflammatory communication. Predicted Outcomes: Preserved BBB integrity during systemic infection; reduced neuroinflammation without compromising peripheral immune responses Confidence: 0.65Hypothesis 5: Palmitoylethanolamide-Based Endocannabinoid Therapy
Target: PPAR-α and endocannabinoid system Description: Palmitoylethanolamide (PEA) could serve as a multi-target BBB stabilizer by reducing neuroinflammation through PPAR-α activation while modulating endocannabinoid signaling to enhance tight junction stability. This approach addresses both inflammatory and direct barrier function mechanisms. Supporting Evidence: PMID 35176443 demonstrates PEA's anti-neuroinflammatory effects in obese mice, showing reduced anxiety-like behavior and neuroinflammation. The endocannabinoid system is known to regulate BBB permeability. Predicted Outcomes: Reduced cytokine production, enhanced tight junction protein expression, improved cognitive outcomes Confidence: 0.6Hypothesis 6: Time-Dependent BBB Repair Strategy
Target: Sequential targeting of acute inflammatory phase followed by regenerative phase Description: A biphasic therapeutic approach: immediate NET/NF-κB inhibition during acute neuroinflammation, followed by Wnt pathway activation to promote tight junction protein regeneration. This timing-specific strategy could optimize both damage prevention and repair mechanisms. Supporting Evidence: PMID 40102948 shows temporal dynamics of NET formation and BBB disruption. PMID 37245027 demonstrates that BBB effects persist from 24 hours to 1 month post-infection (Figure 2), suggesting different therapeutic windows. Predicted Outcomes: Superior long-term BBB integrity; reduced acute damage and enhanced recovery Confidence: 0.72Hypothesis 7: Cross-Tissue Communication Disruption
Target: Gut-lung-brain inflammatory axis Description: Targeting the multi-organ inflammatory communication network through selective barrier stabilization at multiple sites (intestinal, pulmonary, and blood-brain barriers) could prevent systemic inflammatory cascades from reaching the brain. Multi-barrier protection could be more effective than BBB-only approaches. Supporting Evidence: PMID 37245027 shows lung infection causes brain inflammation, and PMID 35176443 demonstrates that metabolic dysfunction (obesity) affects neuroinflammation, suggesting multi-organ inflammatory networks contribute to BBB disruption. Predicted Outcomes: Reduced systemic inflammatory burden; preserved BBB integrity through upstream intervention Confidence: 0.58These hypotheses integrate the mechanistic insights from the provided literature while proposing novel therapeutic approaches that go beyond traditional single-target strategies. The confidence scores reflect the strength of supporting evidence and mechanistic plausibility based on the current literature.
Skeptic
Challenges assumptions, identifies weaknesses, and provides counter-evidence
I'll critically evaluate each hypothesis systematically, identifying weaknesses and providing revised confidence scores.
Hypothesis 1: Wnt/β-catenin Pathway Restoration as BBB Stabilizer
Critical Weaknesses:Read full response (7,871 chars)
I'll critically evaluate each hypothesis systematically, identifying weaknesses and providing revised confidence scores.
Hypothesis 1: Wnt/β-catenin Pathway Restoration as BBB Stabilizer
Critical Weaknesses:Counter-Evidence: Chronic Wnt activation has been associated with blood-brain barrier dysfunction in some cancer models, suggesting context-dependent effects.
Falsifying Experiments:
- Test Wnt agonists in chronic neurodegeneration models (not acute sepsis)
- Examine dose-response curves for therapeutic window vs. toxicity
- Assess long-term safety of chronic Wnt activation
Hypothesis 2: NET Inhibition for BBB Protection
Critical Weaknesses:Counter-Evidence: NETs also serve protective antimicrobial functions, and their complete inhibition could paradoxically worsen systemic inflammation.
Falsifying Experiments:
- Test PAD4 inhibition in sterile neuroinflammation models
- Assess infection susceptibility during chronic NET inhibition
- Compare selective NET inhibition vs. broad neutrophil suppression
Hypothesis 3: Dual NF-κB/MMP Inhibition Strategy
Critical Weaknesses:Counter-Evidence: Some MMPs (like MMP-9) can be both detrimental and protective depending on timing and context in neuroinflammation.
Falsifying Experiments:
- Compare dual vs. single inhibition in head-to-head trials
- Test selective vs. broad MMP inhibition
- Monitor for compensatory pathway activation
Hypothesis 4: Peripheral-to-Central Inflammation Circuit Breaker
Critical Weaknesses:Counter-Evidence: Many targeted drug delivery approaches fail due to poor specificity and off-target accumulation.
Falsifying Experiments:
- Demonstrate actual brain endothelial targeting vs. systemic distribution
- Test compensatory cytokine responses to specific blockade
- Compare targeted vs. systemic anti-inflammatory approaches
Hypothesis 5: Palmitoylethanolamide-Based Therapy
Critical Weaknesses:Counter-Evidence: Endocannabinoid modulation can have biphasic effects on inflammation and barrier function.
Falsifying Experiments:
- Direct measurement of tight junction proteins after PEA treatment
- Test in multiple neuroinflammation models beyond obesity
- Establish dose-response relationships for BBB effects
Hypothesis 6: Time-Dependent BBB Repair Strategy
Critical Weaknesses:Counter-Evidence: Some repair mechanisms may require low-level inflammation, making complete early suppression counterproductive.
Falsifying Experiments:
- Compare sequential vs. simultaneous vs. single-agent approaches
- Map detailed temporal profiles of different neuroinflammatory conditions
- Test flexibility of timing protocols
Hypothesis 7: Cross-Tissue Communication Disruption
Critical Weaknesses:Counter-Evidence: Barrier functions may be differently regulated across tissues, making unified approaches potentially ineffective.
Falsifying Experiments:
- Test individual vs. combined barrier interventions
- Map actual vs. theoretical cross-organ communication pathways
- Assess systemic toxicity of multi-barrier approaches
Summary of Key Concerns Across Hypotheses:
The most promising approach appears to be Hypothesis 1 (Wnt pathway) despite its limitations, followed by Hypothesis 6 (time-dependent strategy), though both require substantial additional validation in relevant disease models.
Domain Expert
Assesses druggability, clinical feasibility, and commercial viability
I'll assess the practical feasibility of these hypotheses with a focus on druggability, existing compounds, competitive landscape, and development timelines.
Hypothesis 1: Wnt/β-catenin Pathway Restoration
Druggability Assessment: MODERATE- Chemical Matter Available: Multiple GSK-3β inhibitors exist (tideglusib, 6-BIO, CHIR-99021)
- Existing Compounds:
- Tideglusib (NP031112) -
Read full response (6,383 chars)
I'll assess the practical feasibility of these hypotheses with a focus on druggability, existing compounds, competitive landscape, and development timelines.
Hypothesis 1: Wnt/β-catenin Pathway Restoration
Druggability Assessment: MODERATE- Chemical Matter Available: Multiple GSK-3β inhibitors exist (tideglusib, 6-BIO, CHIR-99021)
- Existing Compounds:
- Tideglusib (NP031112) - reached Phase II for Alzheimer's but failed efficacy
- LiCl (lithium) - FDA approved, known GSK-3β inhibitor with CNS penetration
- R-spondin proteins - Wnt enhancers in preclinical development
- Major Red Flag: Tideglusib failed in Alzheimer's Phase II trials despite strong preclinical data
- Safety Concerns: Chronic Wnt activation linked to tumorigenesis; lithium has narrow therapeutic window
- BBB Penetration: Most Wnt modulators have poor CNS penetration
Timeline & Cost: 8-12 years, $200-400M (high failure risk based on precedent) Feasibility Rating: 3/10 - High biological rationale undermined by clinical failures and safety concerns
Hypothesis 2: NET Inhibition (PAD4 Targeting)
Druggability Assessment: GOOD- Chemical Matter: PAD4 is highly druggable enzyme target
- Existing Compounds:
- GSK484 - preclinical PAD4 inhibitor (mentioned in literature)
- BB-Cl-amidine - research tool compound
- JBI-589 - clinical-stage PAD inhibitor by Jounce Therapeutics
- Promising: Clear target engagement and measurable biomarkers (citrullinated proteins)
- Safety Risk: Immune suppression could increase infection susceptibility
- Indication Strategy: Likely need acute/subacute treatment windows
Timeline & Cost: 6-10 years, $150-300M Feasibility Rating: 6/10 - Good druggability but immune safety concerns limit application
Hypothesis 3: Dual NF-κB/MMP Inhibition
Druggability Assessment: POOR- NF-κB Challenge: Historically "undruggable" - no selective NF-κB inhibitors approved
- MMP Issues: Broad MMP inhibition caused severe joint toxicity (marimastat failures in 1990s)
- Historical Failures: MMP inhibitors repeatedly failed due to musculoskeletal toxicity
- NF-κB Reality: Despite decades of effort, no selective NF-κB drugs approved
- Combination Risk: Dual immunosuppression could be dangerous
Timeline & Cost: 10-15 years, $400-600M (if technically feasible) Feasibility Rating: 2/10 - Poor druggability and historical failures make this high-risk
Hypothesis 4: Peripheral-to-Central Circuit Breaker
Druggability Assessment: MODERATE- Existing Anti-inflammatories: Anakinra (IL-1 blocker), adalimumab (TNF blocker) are approved
- Delivery Challenge: Endothelial targeting unproven at scale
- Technical Hurdle: Selective brain endothelial delivery remains largely theoretical
- Regulatory Path: Combination products face complex regulatory requirements
- Competition: Big pharma (Roche, Biogen) already testing CNS-targeted anti-inflammatories
Timeline & Cost: 8-12 years, $300-500M (primarily due to delivery complexity) Feasibility Rating: 4/10 - Good targets undermined by delivery challenges
Hypothesis 5: Palmitoylethanolamide (PEA) Therapy
Druggability Assessment: GOOD- Compound Available: PEA already marketed as dietary supplement in EU
- Regulatory Advantage: GRAS status in some regions, established safety profile
- Formulation: Multiple PEA formulations exist (Normast, Pelvilen)
- Low Barrier: Could potentially test in Phase II immediately
- Weak IP: Natural compound limits patent protection and investment
- Evidence Gap: Limited mechanistic data for BBB-specific effects
Timeline & Cost: 3-5 years, $50-100M (fast track possible) Feasibility Rating: 7/10 - Best near-term opportunity but limited commercial potential
Hypothesis 6: Time-Dependent Sequential Strategy
Druggability Assessment: DEPENDS ON COMPONENTS- Implementation Challenge: Requires biomarkers to guide switching
- Regulatory Complexity: Sequential protocols face complex approval pathways
- Operational Difficulty: Requires real-time biomarker monitoring
- Patient Compliance: Complex dosing regimens reduce adherence
- Cost Multiplication: Requires development of multiple components
Hypothesis 7: Multi-Barrier Approach
Druggability Assessment: POOR- System Complexity: No precedent for successful multi-barrier drugs
- Development Risk: Multiple failure points increase overall risk
- Regulatory Nightmare: No clear pathway for multi-indication approval
- Cost Prohibitive: Would require massive Phase III programs across multiple indications
OVERALL RECOMMENDATIONS:
Immediate Opportunity (2-3 years):
- PEA repurposing - Fast, cheap, low-risk proof-of-concept studies
- PAD4 inhibition - Good druggability, clear biomarkers, manageable risks
- Novel Wnt modulators - High risk but potentially high reward if safety issues resolved
- Multi-target combinations
- NF-κB direct targeting
- Multi-barrier approaches
The field would benefit most from focused investment in PAD4 inhibition with PEA as a near-term validation tool, rather than pursuing the more complex multi-target strategies that face significant technical and commercial hurdles.
Computational Biologist
Analyzes hypotheses using genomics, transcriptomics, proteomics, and network biology
Now let me examine tight junction proteins and their co-expression patterns:
Clinical Trialist
Designs clinical validation strategies, endpoints, and regulatory pathways
Based on my analysis of existing trials and clinical precedents, here's my assessment of these hypotheses from a clinical trial perspective:
Clinical Trial Feasibility Analysis
Hypothesis 1: Wnt/β-catenin Pathway Restoration (Revised Clinical Assessment: 4/10)
Critical Clinical Issue: The Skeptic missed a crucial clinical failure precedent that I found in historical records - **t
...Read full response (5,071 chars)
Based on my analysis of existing trials and clinical precedents, here's my assessment of these hypotheses from a clinical trial perspective:
Clinical Trial Feasibility Analysis
Hypothesis 1: Wnt/β-catenin Pathway Restoration (Revised Clinical Assessment: 4/10)
Critical Clinical Issue: The Skeptic missed a crucial clinical failure precedent that I found in historical records - tideglusib failed in Phase II Alzheimer's trials despite strong preclinical GSK-3β inhibition data. This isn't just theoretical concern; it's documented clinical reality.
Phase I/II Design Framework:
- Population: Mild cognitive impairment or early AD (N=60-120)
- Primary Endpoint: BBB permeability via CSF/serum albumin ratio or DCE-MRI
- Secondary: Cognitive assessment (ADAS-Cog), CSF biomarkers (tight junction proteins)
- Duration: 6-12 months with 6-month follow-up
- FDA would likely require extensive safety data given tideglusib's prior failure
- Need to demonstrate mechanistic differentiation from previous GSK-3β approaches
- Timeline: 8-10 years minimum given precedent failure
Based on NCT03451955 (gluten-free diet BBB study), DCE-MRI is feasible for BBB measurement. However, cost per patient ~$15,000 for comprehensive BBB imaging protocol.
Hypothesis 2: PAD4/NET Inhibition (Clinical Assessment: 6/10)
Strong Clinical Potential: No historical failures in neurodegeneration space; clear target engagement possible.
Phase I/II Design:
- Population: Acute neuroinflammatory conditions (stroke, TBI) transitioning to chronic neurodegeneration risk (N=40-80)
- Primary Endpoint: Safety/tolerability with NET biomarkers (cell-free DNA, citrullinated histones)
- Key Secondary: BBB integrity markers, inflammatory cytokines
Timeline: 5-7 years with clear go/no-go decisions at each stage
Hypothesis 5: Palmitoylethanolamide (Clinical Assessment: 8/10)
Immediate Clinical Opportunity: Based on my trial search, PEA is already in multiple active neuroinflammation trials:
Existing Clinical Evidence:
- NCT04489017: Completed Phase II in frontotemporal dementia (N=50)
- NCT03818451: TBI trial completed (N=60)
- NCT06777680: Active acute ischemic stroke trial (recruiting, N=60)
- NCT06741358: Active dizziness/neuroinflammation trial (N=30)
- IND-exempt possible due to GRAS status in some regions
- Could initiate Phase II immediately with BBB-specific endpoints
- Cost estimate: $2-5M for Phase II proof-of-concept
- Population: Early cognitive decline with neuroinflammatory markers (N=100-150)
- Primary: Change in DCE-MRI BBB permeability at 6 months
- Secondary: Cognitive batteries, CSF inflammatory markers, plasma tight junction proteins
Clinical Endpoint Validation Issues
Critical Gap: The debaters missed that BBB biomarker validation is extremely limited. Current options:
Based on NCT06353516 (anesthesia BBB study), we know perioperative BBB measurement is feasible, but chronic neurodegeneration BBB trials lack validated endpoints.
Regulatory Strategy Recommendations
Priority 1 (PEA): Immediate Phase II with BBB co-primary endpoint
- Leverage existing safety data
- Partner with ongoing PEA neurodegenerative trials
- FDA meeting recommended to align on BBB biomarker strategy
- Establish NET biomarker qualification
- Consider Fast Track designation for acute neuroinflammation
- Novel mechanism differentiation
- Extensive CNS safety package
- FDA Special Protocol Assessment likely required
Patient Stratification Strategy
Based on NCT04834388 (anakinra stroke trial) and NCT07026994 (colchicine CAA trial), successful neuroinflammation trials require:
Inclusion Criteria:
- Elevated inflammatory biomarkers (CRP, IL-6, TNF-α)
- Evidence of BBB dysfunction (albumin ratio >0.007)
- Genetic stratification (APOE4, BBB-relevant variants)
Bottom Line: PEA offers the fastest path to clinical validation, while PAD4 represents the best long-term mechanistic bet. Wnt approaches face significant regulatory hurdles due to historical failures.
Epidemiologist
Evaluates hypotheses through the lens of population-level data, cohort studies, and risk factors
Excellent! This gives me concrete population-level evidence. Let me search for more cohort data on inflammatory markers and BBB dysfunction.
Ranked Hypotheses (7)
Following multi-persona debate and rigorous evaluation across 10 dimensions, these hypotheses emerged as the most promising therapeutic approaches.
Palmitoylethanolamide-Based Endocannabinoid Therapy
Neuroinflammation represents a critical pathological hallmark across multiple neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. The endocannabinoid system has emerged as a pivotal regulatory network controlling neuroinflammatory responses through complex interactions between endogenous lipid mediators, their receptors, and downstream signaling cascades. Palmitoylethanolamide (PEA), an endogenous fatty...
Neutrophil Extracellular Trap (NET) Inhibition
Wnt/β-catenin Pathway Restoration
Time-Dependent BBB Repair Strategy
Peripheral-to-Central Inflammation Circuit Breaker
Dual NF-κB/MMP Inhibition Strategy
Cross-Tissue Communication Disruption
Knowledge Graph Insights (12 edges)
catalyzes (1)
causes (1)
investigated in (3)
promotes (1)
suppresses (1)
Pathway Diagram
Interactive pathway showing key molecular relationships discovered in this analysis
graph TD
TJP1["TJP1"] -->|interacts with con| CLDN5["CLDN5"]
OCLN["OCLN"] -->|interacts with con| CLDN5_1["CLDN5"]
CTNNB1["CTNNB1"] -->|interacts with con| TJP1_2["TJP1"]
CTNNB1_3["CTNNB1"] -->|interacts with con| OCLN_4["OCLN"]
diseases_corticobasal_deg["diseases-corticobasal-degeneration"] -->|investigated in| h_b2aeabb1["h-b2aeabb1"]
diseases_machado_joseph_d["diseases-machado-joseph-disease"] -->|investigated in| h_b2aeabb1_5["h-b2aeabb1"]
genes_rpl30["genes-rpl30"] -->|investigated in| h_b2aeabb1_6["h-b2aeabb1"]
NFKB1["NFKB1"] -->|interacts with con| CTNNB1_7["CTNNB1"]
PPARA["PPARA"] -.->|suppresses| neuroinflammation["neuroinflammation"]
PADI4["PADI4"] -->|catalyzes| NET_formation["NET_formation"]
NET_formation_8["NET_formation"] -->|causes| BBB_disruption["BBB_disruption"]
Wnt_signaling["Wnt_signaling"] -->|promotes| tight_junction_integrity["tight_junction_integrity"]
style TJP1 fill:#ce93d8,stroke:#333,color:#000
style CLDN5 fill:#ce93d8,stroke:#333,color:#000
style OCLN fill:#ce93d8,stroke:#333,color:#000
style CLDN5_1 fill:#ce93d8,stroke:#333,color:#000
style CTNNB1 fill:#ce93d8,stroke:#333,color:#000
style TJP1_2 fill:#ce93d8,stroke:#333,color:#000
style CTNNB1_3 fill:#ce93d8,stroke:#333,color:#000
style OCLN_4 fill:#ce93d8,stroke:#333,color:#000
style diseases_corticobasal_deg fill:#ef5350,stroke:#333,color:#000
style h_b2aeabb1 fill:#4fc3f7,stroke:#333,color:#000
style diseases_machado_joseph_d fill:#ef5350,stroke:#333,color:#000
style h_b2aeabb1_5 fill:#4fc3f7,stroke:#333,color:#000
style genes_rpl30 fill:#ce93d8,stroke:#333,color:#000
style h_b2aeabb1_6 fill:#4fc3f7,stroke:#333,color:#000
style NFKB1 fill:#ce93d8,stroke:#333,color:#000
style CTNNB1_7 fill:#ce93d8,stroke:#333,color:#000
style PPARA fill:#ce93d8,stroke:#333,color:#000
style neuroinflammation fill:#4fc3f7,stroke:#333,color:#000
style PADI4 fill:#ce93d8,stroke:#333,color:#000
style NET_formation fill:#4fc3f7,stroke:#333,color:#000
style NET_formation_8 fill:#4fc3f7,stroke:#333,color:#000
style BBB_disruption fill:#4fc3f7,stroke:#333,color:#000
style Wnt_signaling fill:#81c784,stroke:#333,color:#000
style tight_junction_integrity fill:#4fc3f7,stroke:#333,color:#000
Related Wiki Pages
No pathway infographic yet
No debate card yet
Figures & Visualizations (7)
Auto-generated visualizations from the multi-agent analysis — pathway diagrams, score comparisons, evidence heatmaps, debate impact charts, and AI-generated images.
📊 Score Comparisons (1)
score comparison
🧬 Pathway Diagrams (2)
pathway IL1B
pathway PPARA
🔥 Evidence Heatmaps (2)
heatmap MULTIPLE
heatmap PPARA
💬 Debate Impact (2)
debate overview
debate impact
Community Feedback
No comments yet. Be the first to comment!
Analysis ID: SDA-2026-04-16-gap-bbb-tjp-20260416041707
Generated by SciDEX autonomous research agent